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Introduction
Pulmonary hypertension (PH) is defined as an increase in mean 
pulmonary arterial pressure ≥25 mmHg at rest as assessed by right heart 
catheterization [1]. The prognosis of patients with PAH has improved 
with modern therapies, but patient outcomes overall remain poor [2,3]. 
Identification of prognostic markers (clinical, laboratorial and genetic) 
to early find high risk subgroups is crucial.
In the recent years, in addition to a better understanding of 
the pathophysiological mechanisms underlying PH, there has been 
significant development of methods and interventions with diagnostic 
and prognostic relevance addressing this disease, with a particular 
interest in biomarkers. Since there is no single variable that provides 
sufficient diagnostic and prognostic information, a comprehensive 
assessment and multidimensional approach is required. In patients 
with PH, the 6-min walk test (6 MWT) distance provides an assessment 
of exercise capacity. Because limited functional capacity profoundly 
influences the clinical status, changes in 6 MWT distance have been 
employed as an endpoint in clinical studies conducted for regulatory 
approval in patients with PH of different etiologies [4,5]. A 15% 
decrease in the 6 MWT distance coupled with other clinical markers 
suggesting deterioration or escalation of medical therapy has been 
included in definitions of “time to clinical worsening” end points [1].
Anthropometric factors, physical activity, chronic illness 
and motivation are known to influence the 6 MWT distance [1]. 
However, the predictive value of some parameters that have been 
utilized as endpoints in overall functional capacity, reflecting PH 
severity, is not well established. Therefore, we aim to establish clinical, 
echocardiographic and laboratorial parameters associated with 6 MWT 
distance and relevant to further prognostic assessment, and to better 
define mechanisms underlying functional changes together with their 
value as markers of disease modification in PH.
Abstract
Introduction: The 6-minute walk test (6 MWT) distance is frequently used in the prediction of pulmonary 
hypertension (PH) prognosis. However, potential surrogates of this measure have not been established. We aim to 
describe the clinical, echocardiographic, and laboratorial criteria determining the 6 MWT distance in patients with PH.
Methods: In 22 consecutive PH patients, functional capacity was evaluated by the 6 MWT distance and compared 
with levels of neurohormonal activation biomarkers and echocardiographic parameters for right ventricular (RV) 
function.
Results: A correlation between the 6 MWT distance and several clinical parameters was found: Borg’s pre-test 
classification (R=-0.46; p=0.038); WHO functional class (p=0.029). Patients with higher levels of aldosterone (R=-0.46; 
p=0.030), renin (R=-0.43; p=0.046) and mid-regional pro-adrenomedullin (MR-proADM, R=-0.53; p=0.009) had worse 
6 MWT performance. The opposite was true for natremia levels (R=0.55; p=0.006). There was a positive correlation 
between the 6 MWT distance and RV global longitudinal peak systolic strain rate and early diastolic strain rate (R=0.49; 
p=0.038 and R=-0.55; p=0.018, respectively). On multivariate analysis, only natremia and early diastolic strain rate 
were predictors of the 6 MWT distance.
Conclusion: The 6 MWT distance correlated with renin-angiotensin-aldosterone system activation and parameters 
for RV myocardial deformation. The new biomarker MR-proADM proved to be useful in the prediction of the functional 
capacity.
Methods
Study design
We carried out a prospective cohort study of 22 consecutive 
PH patients followed in PH clinic. Inclusion criteria comprised the 
presence of symptomatic (WHO functional class II-IV) PH types I 
and IV (clinical classification [1]). PH was defined as mean pulmonary 
artery pressure ≥25 mmHg, assessed by right heart catheterization. 
Patients were excluded if they had a history of surgery or major trauma 
in the two months prior to inclusion, active neoplastic disease, liver 
cirrhosis or myocardial infarction. All patients were treated according 
to the European Society of Cardiology/European Respiratory Society 
(ESC/ERS) recommendations [4]. The study was approved by local 
ethics committee.
Patients underwent clinical assessment with WHO functional class 
and Borg Scale for Perceived Dyspnea along with echocardiographic 
evaluation and exercise capacity assessment through 6 MWT.
Biochemical analyses
Several biomarkers were determined: uric acid, amino-terminal 
pro-brain natriuretic peptide (NT-proBNP), troponin I, mid-regional 
pro-adrenomedullin (MR-proADM) and aldosterone.
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EDTA-plasma samples were collected from an antecubital vein 
after 5 minutes of rest. Complete blood and platelet counts, serum 
creatinine, sodium, urea, uric acid, troponin I, NT-proBNP, aldosterone 
and renin were processed and analyzed in the hospital laboratory. NT-
proBNP levels were determined on solid phase immunometric assay 
Immulite 2000 (Siemens Healthcare Global®, Breda, The Netherlands), 
commercially available and validated in the clinic. Blood osmolality 
was calculated using the following formula: osmolality=1.86 × [sodium 
(mmol/L)]+[glucose (mg/dL)]/18+[Urea (mg/dL)]/5992+9. Aliquots 
of plasma samples were stored at -80°C for further analysis.
Echocardiography
A GE Vivid 7 Dimension® echocardiography machine was 
used. Digital images were post-processed in EchoPAC Dimension 
software (GE Healthcare®, Milwaukee, WI). All patients underwent 
a complete transthoracic echocardiogram, performed according to 
the recommendations of the American Society of Echocardiography 
[6-8]. Standard two-dimensional echocardiographic evaluation of 
left ventricular (LV) and right ventricular (RV) size and function 
was performed. The following indices were obtained from the apical 
4-chamber view: RV basal end-diastolic dimension; RV fractional 
area change [(RV end-diastolic area – RV end-systolic area)/RV end-
diastolic area]; and maximal tricuspid annular plane systolic excursion 
(TAPSE). RV wall thickness was measured from the subcostal view. 
The peak tricuspid regurgitation velocity, recorded by continuous wave 
Doppler echocardiography, was selected from multiple standard views 
and the values from 3 consecutive beats were averaged. The pulmonary 
artery systolic pressure was calculated as the sum of the peak systolic 
tricuspid pressure gradient (calculated by modified Bernoulli equation 
from peak tricuspid regurgitation velocity) and estimated right atrial 
pressure (according to inferior vena cava size and respiratory kinetics).
Colour-coded tissue Doppler images of the RV free wall were 
obtained from the apical 4-chamber view ensuring a frame rate 
of >100 frames/s. Speckle-tracking analysis was used to generate 
regional myocardial strain and displacement. RV longitudinal strain 
was assessed in apical four-chamber views. Myocardial deformation 
was expressed as the percentage change from the original dimension 
at end-diastole. Myocardial lengthening was represented as a positive 
value and myocardial shortening was represented as a negative value. 
Values obtained in the basal and mid-ventricular segments were 
averaged together to obtain the following measurements: RV peak 
global longitudinal systolic strain; RV peak global longitudinal systolic 
strain rate (GLSRs); RV peak global longitudinal early diastolic strain 
rate (GLSRe); RV peak global longitudinal end-diastolic strain rate 
(GLSRa).
Statistical analysis
Continuous variables were presented as median and inter-quartile 
range. Categorical variables were presented as a number and percentage. 
The differences between these variables were calculated using the chi-
square test. The multivariate model was based on an algorithm using all 
biomarkers tested.
Correlations between MR-proADM and other variables were 
explored using Pearson’s test. A p-value ≤0.05 was considered significant 
in all tests. The statistical software IBM SPSS Statistics® version 20.0 
(IBM GmbH, Ehningen, Germany) was used.
Results
Detailed clinical, laboratorial and echocardiographic characteristics 
of the 22 patients are described in Table 1. The median age was 60.0 
Variables’ Global (n=22)
Clinic and Demographic  
Age (years), median (IQR) 60.0 (43.0-67.5)
Female gender, No. (%) 15 (68)
Etiologic classification (Dana Point)  
-Group I, No. (%) 17 (77)
-Group IV, No. (%) 5 (23)
Mean PAP (cath, mmHg), median (IQR) 46.5 (36.8-55.0)
Vasoreactivity, No. (%) 3.0 (11.0)
WHO class  
-Class II, No (%) 16 (73)
-Class III, No. (%) 4 (18)
-Class IV, No. (%) 2 (9)
6MWT distance, median (IQR) 352.5 (253.0-419.0)
Baseline treatment, No. (%)  
-Calcium channel blockers 6 (27)
-Endothelin antagonists 12 (54)
-Phosphodiesterase inhibitors 3 (14)
-Parenteral prostacyclin analogues 8 (36)
-Inhaled iloprost 3 (14)
-Diuretic 18 (82)
Blood tests, median (IQR)  
Uric acid (mg/dL) 5.9 (4.8-7.0)
NT-proBNP (pg/mL) 1029.5 (220.0-1702.3)
MR-proADM (nmol/L) 0.7 (0.5-1.0) 
Troponin I (pmol/L) 0
Aldosterone (nmol/L) 93.7 (44.3-163.0)
Renin (ng/mL) 11.0 (2.9-22.6)
Sodium (mmol/L) 140.0 (138.0-141.5)
Echocardiography, median (IQR)  
Estimated PASP (mmHg) 73.0 (59.0-87.5)
RV end-diastolic diameter (mm) 39.5 (31.0-48.3)
RV wall thickness (mm) 5.2 (5.0-6.1)
Right atrial diameter (mm) 54.0 (48.5-69.5)
IVC inspiratory collapse (%) 51.5 (29.3-85.8)
RV fractional area change (%) 32.6 (22.2-42.3)
TAPSE (mm) 18.5 (15.0-23.3)
Tricuspid TDI Sm velocity (cm/s) 11.5 (8.8-13.3)
RV global longitudinal systolic strain (%) -15.1 (-21.3 to -12.3)
RV global longitudinal systolic strain rate (/s, 
GLSRs) -1.0 (-1.2 to -0.7)
LV end-diastolic diameter (mm) 45.5 (41.8-50.5)
LV EF (%) 58.5 (58.5-68.8)
RV global longitudinal peak early diastolic strain 
rate (GLSRe) 0.9 (0.6-1.2)
RV global longitudinal peak end-diastolic strain 
rate (GLSRa) 0.8 (0.5-1.0)
6MWT: 6-Minute Walk Test; ESR: Erythrocyte Sedimentation Rate; IVC: Inferior 
Vena Cava; LV: Left Ventricular; PAP: Pulmonary Artery Pressure; PASP: Pulmonary 
Artery Systolic Pressure; RV: Right Ventricular; TAPSE: Tricuspid Annular Peak 
Systolic Excursion; TDI: Tissue Doppler Imaging; WHO: World Health Organization.
Table 1: Baseline clinical, laboratorial and echocardiographic characteristics.
(IQR, 43.0 to 67.5) years-old. The majority of patients were female 
(68%, n=15). Etiologic investigation disclosed inoperable chronic 
thromboembolic disease as the cause of PH in 5 patients (23%). The 
remaining 17 patients had etiologies that met Group I (Nice criteria 
2013). All patients were symptomatic, with 73% having WHO class II 
symptoms.
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A negative correlation was seen between the 6 MWT distance and 
WHO functional class (S=-0.48, p=0.021) and the pretest Borg scale 
(S=-0.52, p=0.017), as shown in Figures 1 and 2, respectively. The 6 
MWT distance also correlated with some laboratorial parameters: 
directly with sodium level (R=0.55, p=0.006) and inversely with serum 
aldosterone (R=-0.46, p=0.030), renin (R=-0.43, p=0.046) and MR-
proADM (R=-0.53, p=0.009) (Figures 3, 4, 5 and 6, respectively).
There was no statistically significant relationship between the 6 
MWT distance and serum levels of NT-proBNP and uric acid.
The only echocardiographic variables that correlated with the 6 
MWT distance were GLSRs (R=0.49, p=0.038) and GLSRe (R=-0.55, 
p=0.018) (Figures 7 and 8, respectively). The conventional parameters 
of the RV function did not show any statistically significant association.
Figure 1: Correlation between 6 MWT distance and WHO functional class 
in 22 PH patients (at inclusion).
Figure 2: Correlation between 6 MWT distance and pretest Borg scale in 
22 PH patients (at inclusion).
Figure 3: Correlation between 6 MWT distance and natremia in 22 PH patients 
(at inclusion). The linear regression line is superimposed, surrounded with the 
95% confidence interval lines for the regression line. r=Pearson correlation 
coefficient. p=p value.
Figure 4: Correlation between 6 MWT distance and serum aldosterone in 
22 PH patients (at inclusion). The linear regression line is superimposed, 
surrounded with the 95% confidence interval lines for the regression line. 
r=Pearson correlation coefficient. p=p value.
Discussion
In the present study, we sought to determine the power of several 
clinical, laboratorial and echocardiographic variables in predicting 
the 6 MWT results in patients with PH. We hypothesized that the 6 
MWT distance correlated with neurohumoral and echocardiographic 
parameters reflecting PH severity.
This study demonstrated that serum concentration of aldosterone, 
renin, MR-proADM and sodium, in addition to right ventricle strain 
imaging parameters, correlated with 6 MWT distance.
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Figure 5: Correlation between 6 MWT distance and renin in 22 PH patients 
(at inclusion). The linear regression line is superimposed, surrounded with the 
95% confidence interval lines for the regression line. r=Pearson correlation 
coefficient. p=p value.
Figure 6: Correlation between 6 MWT distance and MR-proADM in 22 
PH patients (at inclusion). The linear regression line is superimposed, 
surrounded with the 95% confidence interval lines for the regression line. 
r=Pearson correlation coefficient. p=p value.
The successful use of the change in 6 MWT distance as a primary 
end-point in the pivotal PH trial of IV Epoprostenol [9] paved the way 
for its use as a primary end-point and indicator of symptom change in 
other trials for PH medications. It is the most widely used functional 
marker because it is derived from a simple test that correlates with 
hemodynamic variables and the results of cardiopulmonary exercise 
testing, as and it has prognostic value in the evalu ation of PH patients 
[1,10,11]. By measuring the distance a patient can walk, the 6 MWT 
can indirectly quantify shortness of breath and fatigue, two of the most 
common symptoms of PH. However, PH is a chronic, progressive, 
Figure 7: Correlation between 6 MWT distance and GLSRs in 22 PH patients 
(at inclusion). The linear regression line is superimposed, surrounded with the 
95% confidence interval lines for the regression line. r=Pearson correlation 
coefficient. p=p value.
Figure 8: Correlation between 6 MWT distance and GLSRe in 22 PH 
patients (at inclusion). The linear regression line is superimposed, 
surrounded with the 95% confidence interval lines for the regression line. 
r=Pearson correlation coefficient. p=p value.
functionally debilitating disease, and the relevance of 6 MWT distance 
to long-term outcomes is questionable.
A correlation exists between increasing exercise capacity and 
the improvement of several peripheral abnormalities, in the absence 
of improvement in hemodynamic abnormalities in patients with 
cardiopulmonary disease [12]. It is possible that the changes that 
occur in the periphery as a consequence of the systemic effects of 
heart failure often become the exercise limiting factors more than the 
heart dysfunction that initiated the syndrome. The complexity of the 
question should raise the importance of a multi-parameter approach in 
the care of patients with PH, to help ensure that measures of functional 
capacity, clinical improvement or worsening and treatment effect are 
determined objectively.
In respect to biomarkers, a large number of neurohumoral peptides 
have shown superiority over those commonly used in heart failure 
and have the potential to be useful in monitoring PH. They offer the 
possibility of reducing the frequency of use of invasive tests and may be 
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particularly useful for screening, predicting the prognosis, monitoring 
and possibly assist in the selection of therapy of PH patients. However, to 
date only brain natriuretic peptide and NT-proBNP have been included 
as prognostic parameters in the guidelines [4]. The natriuretic peptide 
system is activated in chronic PH [13,14]. NT-proBNP levels have been 
related to hemodynamic and functional parameters [15,16], response 
to medical treatment [17] and mortality in patients with PH [18,19]. 
Neurohormonal activation of the sympathetic and renin–angiotensin-
aldosterone system has been demonstrated in patients with PH, and 
occurs in proportion to the degree of RV dysfunction [20]. Systemic 
renin-angiotensin-aldosterone activity is increased in patients with PH 
and associated with disease progression. Due to increased angiotensin 
converter enzyme activity, pulmonary endothelial cells of patients with 
PH produce more angiotensin II, which in turn induces significant 
proliferation of pulmonary artery smooth muscle cell, RV afterload and 
pulmonary vascular remodeling [21]. Several studies have showed the 
importance of natremia in the evaluation of patients with PH. Forfia et 
al demonstrated that hyponatremia is associated with advanced right 
heart failure and reduced survival in patients with PH and predicted 
death even after adjusting for hemodynamic, echocardiographic 
and clinical variables of known prognostic importance in PH [22]. 
Our results suggested that natremia and neurohormonal activation 
biomarkers of the renin-angiotensin-aldosterone system correlate with 
functional capacity in patients with PH, likely reflecting differences in 
pulmonary and systemic hemodynamics. Of note, our patients were not 
treated with angiotensin converting enzyme inhibitors or angiotensin 
receptor blockers antagonists.
Plasma adrenomedullin is a potent hypotensive peptide that 
increases pulmonary blood flow. One study demonstrated that plasma 
adrenomedullin levels were increased in patients with pulmonary 
arterial hypertension compared with control subjects. Right atrial 
pressure, mean pulmonary arterial pressure, and pulmonary vascular 
resistance were highly correlated with adrenomedullin levels [23]. Our 
study is the first to show a correlation between MR-proADM levels 
and the 6 MWT results in PH. Patients with a worse performance on 
6 MWT had higher levels of MR-proADM, which may be reflecting 
a compensatory mechanism regarding the vasodilatatory properties of 
the peptide.
RV function is an important determinant of outcome in PH, 
however, its evaluation is challenging because of its geometry. Speckle-
tracking strain echocardiographic evaluation is an easily obtained, 
angle-independent technique for quantifying myocardial deformation 
[24-27], including assessment of RV function in PH [28,29]. Sachdev 
et al. [30] showed that RV longitudinal systolic function by strain 
and strain rate independently predict future right-sided heart failure, 
clinical deterioration and mortality in patients with pulmonary 
arterial hypertension (PAH). An RV free wall strain below -12.5% in 
patients with PAH identified a cohort with marked RV dysfunction and 
predisposition to clinical deterioration.
In this study, we did not find a correlation between functional 
capacity (expressed by the 6 MWT distance) and RV global longitudinal 
systolic strain or TAPSE. However, it was found that patients with poor 
performance in the 6 MWT had higher RV global longitudinal systolic 
strain rate. Although the distinction between increased afterload or 
impaired contractility or both as the cause of deformation variability 
is difficult and may warrant further investigation, we propose that this 
finding may reflect adaptive changes of RV mechanics induced by PH.
Insight into the role of diastolic function in PH patients is scarce. In 
the past years, research has mainly focused on the influence of PH on 
RV systolic function and the prognostic significance of this parameter 
[30]. There is evidence that RV diastolic function is impaired in PH 
patients. First, due to increased RV afterload, myocardial relaxation and 
filling may be impaired. Second, the RV compensatory hypertrophy in 
response to increased afterload reduces ventricular compliance and 
may impair diastolic function [31]. We found that GLSRe showed an 
inverted correlation with the 6 MWT distance, possibly reflecting some 
degree of diastolic dysfunction due to pressure overload and secondary 
remodeling.
We recognize several limitations of our study. The number of 
subjects included is small, but in low prevalence diseases such as PH 
amassing a large population of patients is rare even in a referral center. 
Patients were on variable therapies at inclusion. In this regard, recent 
meta-analysis of PH trials have consistently shown that while baseline 6 
MWT distance strongly predicts survival, changes in 6 MWT distance 
in response to specific therapies did not predict disease outcomes 
[11,32]. Furthermore, there are intrinsic limitations of speckle-tracking 
strain echocardiography including relatively low reproducibility with 
suboptimal intra- and interobserver variabilities, broad ranges of 
normal values due to patient-to-patient variability, dependence on 
image quality and frame rate and image resolution.
Conclusion
In conclusion, the 6 MWT distance correlated with the activation 
of the renin-angiotensin-aldosterone system and parameters of RV 
myocardial deformation. The MR-proADM levels proved to be useful 
in the prediction of the functional capacity.
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